Wall Street analysts kicked off the week by turning more optimistic on a handful of companies spanning everything from energy giants to freight haulers to biotech upstarts. Here's what changed hands on Monday morning's upgrade list.
HSBC analyst Kim Fustier upgraded Chevron Corp (CVX) from Hold to Buy, nudging the price target higher from $166 to $169. The energy company closed Friday at $151.13, suggesting Fustier sees meaningful upside ahead for the oil major.
In the transportation sector, BMO Capital analyst Fadi Chamoun made an interesting move on Old Dominion Freight Line Inc (ODFL), upgrading the trucking company from Market Perform to Outperform. The twist? Chamoun actually lowered the price target slightly, from $172 to $170. That said, with shares closing Friday at $135.29, there's still a decent gap between the current price and where the analyst thinks it's headed. Sometimes an upgrade with a lower target signals that while near-term expectations have adjusted, the risk-reward profile has improved enough to get more constructive.
BNP Paribas Exane analyst Thomas Poutrieux upgraded Toast Inc (TOST) from Neutral to Outperform, setting a $40 price target on the restaurant technology platform. Toast shares ended Friday at $34.19, giving the stock some room to run if Poutrieux's thesis plays out.
Over in biotech land, RBC Capital analyst Brian Abrahams got significantly more bullish on Neumora Therapeutics Inc (NMRA), upgrading the neuroscience-focused company from Sector Perform to Outperform. The real eye-catcher here is the price target jump from $4 to $7—a 75% increase that suggests something material has changed in Abrahams' view of the company's prospects. Neumora shares closed at $2.24 on Friday, meaning the new target implies more than a triple from current levels.
Finally, Jones Trading analyst Debanjana Chatterjee upgraded Spyre Therapeutics Inc (SYRE) from Hold to Buy, announcing a $64 price target. With Spyre closing Friday at $30.00, that's more than a double if Chatterjee's forecast proves accurate.
These upgrades represent fresh conviction from analysts who cover these companies closely, though as always, price targets are educated guesses rather than guarantees. Still, when an analyst changes their rating, it typically signals that something in their analysis has shifted—whether it's better-than-expected fundamentals, improving industry dynamics, or simply a stock price that's fallen enough to make the risk-reward more attractive.
